FDA OKs Phase 2 Trial Evaluating 2X-121 in Advanced Ovarian Cancer Patients

FDA OKs Phase 2 Trial Evaluating 2X-121 in Advanced Ovarian Cancer Patients
The U.S. Food and Drug Administration has green-lighted a Phase 2 clinical trial that will assess the safety and effectiveness of the small molecule 2X-121 in advanced ovarian cancer patients, Oncology Venture has announced. The trial will also use the 2x-121 Drug Response Predictor biomarker to identify patients likely to respond to and benefit from treatment with 2X-121. The 2x-121 Drug

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *